After Hours
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. After-hours trades for Gilead Sciences, Inc. (GILD) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.01, or -0.01%, to $86.37. The Gilead Sciences, Inc. has recorded 535,659 volume in the after hours trading session. Most recently, Yahoo Finance reported about the stock as it publicized that Gilead Pays Tribute to Patient Advocacy Work: Cara’s Story.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
This NASDAQ-listed company operates within the Drug Manufacturers – General industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $86.38 and fluctuated between $86.44 as its day high and $85.64 as its day low. The current market capitalization of Gilead Sciences, Inc. is $107.63B. A total of 5.8 million shares were traded on the day, compared to an average of 6.50M shares.
Insider Activity
Insider trades can also provide insight into a stock’s future direction. During the recent three months, GILD has seen 2 BUY and 3 SELL insider trades, representing the acquisition of 2,426 and the disposition of 6,047 shares. Over the last 12 months, there were 49 BUYs and 36 SELLs from insiders. Insiders purchased 586,538 shares during that period but sold 214,404.
In the most recent transaction, Mercier Johanna sold 8,242 shares of GILD for 85.23 per share on Jan 09. After the transaction, the Chief Commercial Officer now owns 82,729 company shares. In a previous transaction on Oct 17, Dickinson Andrew D sold 5,000 shares at 80.00 per share. GILD shares that Chief Financial Officer owns now total 104,003.
Among the insiders who sold shares, Parsey Merdad disposed of 1,501 shares on Sep 12 at a per-share price of $76.99. This resulted in the Chief Medical Officer holding 70,130 shares of GILD after the transaction. In another insider transaction, Dickinson Andrew D sold 5,000 shares at $80.00 per share on Jul 20. Company shares held by the Chief Financial Officer now total 107,587.
Dividend
The income generated by dividends is an indication that a company is improving its financial position, which is why investors prefer companies paying dividends. Gilead Sciences, Inc. pays an annual dividend of $3.08, resulting in a dividend yield of 3.57%, and it has a price to earnings (P/E) ratio of 18.52. GILD’s most recent ex-dividend date was 12/14/2023 when it declared a $0.75 quarterly dividend that was paid in cash on 12/28/2023. Previously, the company paid the dividend on 9/28/2023 with an ex-dividend date of 9/14/2023. The GILD stock dividend was $0.75 per share in cash.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for GILD in the last 3 months, the mean price target is $89.57 with high estimates of $116.00 and low estimates of $69.00. In terms of 52-week highs and lows, GILD has a high of $87.82 and a low of $72.87.
As of this writing, GILD has an earnings estimate of $1.79 per share for the current quarter. EPS was calculated based on a consensus of 23 estimates, with a high estimate of $2.04 per share and a lower estimate of $1.64. The company reported an EPS of $1.34 in the last quarter, which was -18.30% lower than expectations of $1.64.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. GILD’s latest balance sheet shows that the firm has $6.52B in Cash & Short Term Investments as of fiscal 2021. There were $26.70B in debt and $11.61B in liabilities at the time. Its Book Value Per Share was $17.89, while its Total Shareholder’s Equity was $21.06B.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for GILD is Buy with a score of 4.05.
